Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Significance: Respiratory syncytial virus is a highly contagious human pathogen, infecting the majority of infants before age 2 y, and is the leading cause of viral bronchiolitis and viral pneumonia in infants and children. An approved prophylactic humanized mouse monoclonal antibody, palivizumab, is currently the standard-of-care treatment for immunocompromised individuals, and competition with palivizumab has been proposed as the basis for measuring effective immune responses for vaccine trials. Using a combination of X-ray crystallography, hydrogen-deuterium exchange, and saturation alanine mutagenesis scanning, we show the structural basis for neutralization by a human antibody at the palivizumab antigenic site. Furthermore, we describe nonneutralizing antibodies that directly compete with palivizumab and another human antibody 14N4. Taken together, the data presented provide unique concepts in structure-based vaccine design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O'Brien, K. L., Roca, A., Wright, P. F., Bruce, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60206-1 · Cited by 2,773 · cited 1×
“RSV remains a top priority for vaccine development, as thousands of deaths are recorded worldwide each year because of complications from infection (3).”
Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus
McLellan, J. S., Chen, M., Joyce, M. G., Sastry, M., Stewart-Jones, G. B. E., Yang, Y., Zhang, B., Chen, L., Srivatsan, S., Zheng, A., et al. (2013) · Science · doi:10.1126/science.1243283 · Cited by 1,126
Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody
McLellan, J. S., Chen, M., Leung, S., Graepel, K. W., Du, X., Yang, Y., Zhou, T., Baxa, U., Yasuda, E., Beaumont, T., et al. (2013) · Science · doi:10.1126/science.1234914 · Cited by 883
Proof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555 · cited 22×
“Strategies included a stable trihelix scaffold protein purpose-built to support the helix–loop–helix motif of antigenic site II (FFL_001) (10), a Fab-based scaffold for site II (24), and also a strategy in which the RSV F site II was grafted onto the metapneumovirus (MPV) F protein (RPM-1) to generate a chimeric prote…”
BackgroundMethodResultInfluentialSelf-citationA highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
Krarup, A., Truan, D., Furmanova-Hollenstein, P., Bogaert, L., Bouchier, P., Bisschop, I. J. M., Widjojoatmodjo, M. N., Zahn, R., Schuitemaker, H., McLellan, J. S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9143 · Cited by 383 · cited 1×
“mAbs were tested for binding by ELISA to postfusion or prefusion-stabilized disulfide-cavity filling (DsCav1) or single chain-triple mutant (SC-TM) RSV strain A2 F proteins (17, 18) and postfusion F from RSV strain 18537 B (Table 1 and Fig.”
Cited by
Mazur, N. I., Higgins, D., Nunes, M. C., Melero, J. A., Langedijk, A. C., Horsley, N., Buchholz, U. J., Openshaw, P. J., McLellan, J. S., Englund, J. A., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30292-5 · Cited by 457
A proof of concept for structure-based vaccine design targeting RSV in humans
Crank, M. C., Ruckwardt, T. J., Chen, M., Morabito, K. M., Phung, E., Costner, P. J., Holman, L. A., Hickman, S. P., Berkowitz, N. M., Gordon, I. J., et al. (2019) · Science · doi:10.1126/science.aav9033 · Cited by 333
Mousa, J. J., Kose, N., Matta, P., Gilchuk, P., & Crowe, J. E. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.271 · Cited by 111
“We recently described the isolation and characterization of several new human mAbs targeting antigenic sites I and II, which were identified by screening for binding to the RSV strain A2 F protein in the post-fusion conformation 14 .”
InfluentialSelf-citationKulkarni, P. S., Hurwitz, J. L., Simões, E. A. F., & Piedra, P. A. (2018) · Viral Immunology · doi:10.1089/vim.2017.0147 · Cited by 53
Metadata
- Authors
- Mousa, J. J., Sauer, M. F., Sevy, A. M., Finn, J. A., Bates, J. T., Alvarado, G., King, H. G., Loerinc, L. B., Fong, R. H., Doranz, B. J., Correia, B. E., Kalyuzhniy, O., Wen, X., Jardetzky, T. S., Schief, W. R., Ohi, M. D., Meiler, J., & Crowe, J. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2016-10-17
- Volume
- 113
- Issue
- 44
- Pages
- E6849-E6858
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2533150511
- Cited by
- 53
- References
- 5
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.